Abstract 230P
Background
Our prior research demonstrated that the presence of detectable plasma levels of acetaminophen (APAP) at the initiation of treatment was associated to a poor clinical outcome in cancer patients receiving immune checkpoint inhibitors (ICIs), independent of other known prognostic factors (Bessede et al. Ann Oncol 2022). This observation raised concerns about the potential immunomodulatory effects of APAP. Consequently, we aimed to elucidate the mechanistic basis of APAP’s immunosuppressive action.
Methods
We established an in vitro model using peripheral blood mononuclear cells (PBMCs) activated with anti-CD3 in the presence of APAP. Cellular responses were assessed at 3 and 6 days post-treatment using live-cell imaging and immunophenotyping via flow cytometry. Cytokine production was quantified through Homogeneous Time-Resolved Fluorescence assays, and key analytes were measured using ELISA.
Results
Our findings revealed that APAP significantly reduced the production of interferon-gamma (IFNγ) and suppressed PBMC proliferation in a dose-dependent manner, independent of cell death pathways. Notably, serotonin and kynurenine pathways did not appear to contribute to the impaired IFNγ response. In the presence of APAP, a distinct subset of CD4+ T cells emerged, characterized by low IFNγ production and expression of exhaustion markers such as Tim-3 and LAG-3, although PD-1 expression remained low. These results suggest that APAP selectively affects a subpopulation of immune cells, driving their exhaustion. Additionally, we identified tramadol and nefopam as viable alternatives to APAP, as neither PBMC cluster formation nor IFNγ production were impaired in our model.
Conclusions
APAP exerts a potent immunosuppressive effect on PBMC activation, promoting the expansion of an exhausted CD4+ T cell subset. Ongoing investigations using single-cell RNA sequencing will provide deeper insights into the phenotypic and functional characteristics of these cells. These findings may have critical implications for the use of APAP in cancer patients undergoing immunotherapy and highlight the potential of alternative analgesics with limited immunomodulatory activity.
Legal entity responsible for the study
The authors.
Funding
Fondation ARC pour la recherche sur le cancer.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
109P - Efficacy of first-line immune-based combined systemic therapy and brain radiotherapy in patients with brain metastases (BM) from driver gene-negative NSCLC
Presenter: Mengxing You
Session: Poster Display session
110P - Safety and effectiveness of adebrelimab as first-line treatment in extensive-stage small-cell lung cancer: A prospective, real-world study
Presenter: Junxu Wen
Session: Poster Display session
111P - Real-world treatment patterns and clinical outcomes in Chinese stage III non-small cell lung cancer (NSCLC) patients: Results of MOOREA study
Presenter: Ligang Xing
Session: Poster Display session
112P - Serplulimab combined with chemotherapy and anlotinib for extensive-stage small-cell lung cancer: A multicenter real-world experience
Presenter: Jun Wang
Session: Poster Display session
113P - Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: An observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)
Presenter: Irene Torresan
Session: Poster Display session
115P - Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors in Germany: A population-based study
Presenter: Lucie Heinzerling
Session: Poster Display session
116TiP - An umbrella trial (RECHALLENGE) to evaluate the safety and preliminary efficacy of combination or sequential immunotherapy in advanced solid tumor patients after disease progression in clinical trials
Presenter: Huilei Miao
Session: Poster Display session
122P - Intracellular adenosine drives profound lymphocyte suppression and can be reversed with EOS-984: A potent ENT1 antagonist
Presenter: Erica Houthuys
Session: Poster Display session
123P - Combination potential of EO-3021, a CLDN18.2 vc-MMAE ADC, with VEGFR2 or PD1 inhibition in preclinical models of CLDN18.2-expressing cancers
Presenter: Thomas O'Hare
Session: Poster Display session